WTO

Covid-19 development round-up: March 18, 2022

The state of the fight: 

Medicines Patent Pool sublicensed Pfizer’s Paxlovid to 35 generics manufacturers.
  Key WTO members reached a tentative agreement to waive some IP rights on Covid-19 vaccines.
  Moderna and Pfizer asked the U.S. FDA to authorize fourth doses of their respective jabs.   AUTHORIZED VACCINES

 
Medigen’s protein subunit vaccine (MVC-COV1901) offered similar safety and immunogenicity for adolescents as it did for adults, the Taipei-based…

Mentions:
Covid-19, vaccines, drugs, Medigen, WHO, Moderna, Sinovac, AstraZeneca, FDA, Pfizer, BioNTech, CanSino, Anhui Longcom, Clover, SII, CureVac, GSK, WTO, COVAX, Gamaleya Institute, Gavi, Bio E, J&J, MPP, DNDi, Vir, Merck, Shionogi
Read more
PhRMA complains over meds access

Washington D.C. lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) is "attacking the WHO" and several governments it accuses of "harming biopharma innovation," Endpoints News reported Wednesday.

In its annual update to the U.S. Trade Representative on the state of IP protection, PhRMA singled out a WHO roadmap for access to medicines and vaccines, faulting the document for urging technical support to countries that pursue compulsory licensing. Notwithstanding…

Mentions:
PhRMA, WHO, WTO, UNITAID, access to medicines, UNDP
Read more
Covid-19 development round-up: June 4, 2021

The state of the hunt: 

WHO cleared Sinovac’s vaccine for emergency use.
  Gavi’s COVAX AMC funding summit exceeded its goals, securing $2.4 billion in commitments.
  India ordered 300 million doses of a yet-to-be-authorized Bio E vaccine candidate. Approved or authorized vaccines

Sinovac’s inactivated vaccine notched WHO Emergency Use Listing on Monday, leaving the shot, CoronaVac, eligible for supply through the COVAX Facility. Less-demanding storage requirements…

Mentions:
Covid-19, vaccines, drugs, Sinovac, WHO, COVAX, Pfizer, BioNTech, AstraZeneca, Moderna, BBIL, Gamaleya Institute, SII, CNBG, Sinopharm, J&J, Shenzhen Kangtai, Valneva, CanSino, Bio E, BMGF, Gavi, IMF, World Bank, WTO, ACT-A, UNICEF, Lilly, GSK, Vir
Read more
Pharma defiant as US backs IP waiver

A leading pharma trade group reacted fiercely to the U.S. government’s Wednesday decision to support a temporary waiver of intellectual property rights for Covid-19 vaccines. The Pharmaceutical Research and Manufacturers of America (PhRMA) said the move would “sow confusion,” “weaken already strained supply chains,” and “foster the proliferation of counterfeit vaccines,” rather than save lives.

Meanwhile, WHO chief Tedros Adhanom Ghebreyesus praised the Biden administration’s decision…

Mentions:
IP, patents, PhRMA, WHO, WTO, TRIPS, MSF, Covid-19, vaccines
Read more
Covid-19 development round-up: April 1, 2021

The state of the hunt:

Pfizer and BioNTech plan to seek authorization of their vaccine for adolescents age 12-15 after promising Phase 3 results.
  J&J agreed to supply up to 400 million doses of Janssen’s jab to the African Union.
  Serum Institute of India launched clinical trials of its version of the Novavax vaccine candidate.

 

Vaccines


Approved or authorized vaccines
   
New data show lower efficacy for Pfizer/BioNTech: The…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, FDA, AstraZeneca, EMA, WHO, Oxford University, CDC, Moderna, NIH, SII, Novavax, CNBG, Sinopharm, Sinovac, J&J, Janssen, BBIL, CanSino, Gritstone Oncology, Iconovo, AVAT, AU, Afreximbank, Emergent, Merck, Ajinomoto Bio-Pharma Services, BIBP, Group 42, RDIF, Gamaleya Institute, TopRidge Pharma, Tibet Rhodiola, Shenzhen Yuanxing Gene-tech, CureVac, Celonic Group, Bio Farma, GSK, CEPI, UNICEF, ACT Accelerator, ACT-A, ACT-A SFF, COVAX AMC, WTO, Africa CDC, MSF, COVAX, Humanigen, Lilly, Vir, Daiichi Sankyo
Read more
Covid-19 development round-up: December 11, 2020

The state of the hunt:

Pfizer/BioNTech’s vaccine won U.S. FDA Emergency Use Authorization.
  The inactivated vaccine from CNBG’s Beijing subsidiary secured UAE registration.
  Bharat Biotech and SII requested Indian authorization of their respective jabs.

 

Vaccines


Approved or authorized vaccines
 
The Pfizer/BioNTech vaccine extended its regulatory lead this week with new authorizations, including a U.S. nod.
 
The U.S.…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Pfizer, BioNTech, FDA, CNBG, Sinopharm, BBIL, SII, EMA, WHO, AstraZeneca, Moderna, Gamaleya Institute, Sinovac, Sino Biopharma, J&J, Janssen, Anges, Inovio, Roche, IMBCAS, University of Queensland, CSL, CEPI, Sanofi, GSK, WUSTL, Gennova, Tonix, SK Bioscience, EuBiologics, KMPC, Providence Therapeutics, Health Canada, BioE, OSU, COVAX AMC, Schott Kaisha, SGD Pharma India, Hindustan Syringes, Snowman, Instituto Butantan, Halix, Duke University, RDIF, Shenzhen Kangtai, CureVac, Fareva, ADB, CDC, Dulas, DHL, Amnesty International, Oxfam, People’s Vaccine, Novavax, IAVI, Lilly, Gilead, APEIRON, Cyxone, Sorrento, University of Louisville, AbCellera, Quest Diagnostics, LabCorp, NIH, QIAGEN, Thermo Fisher, BMGF, WTO
Read more
Covid-19 development round-up: October 9, 2020

The state of the hunt:

China will join the COVAX Facility, its foreign ministry announced Thursday.
  Regeneron requested U.S. FDA emergency authorization for a monoclonal antibody cocktail, and Eli Lilly planned a similar request for its mAb cocktail in November. 
  Remdesivir showed expanded benefits in final Phase 3 results published in the New England Journal of Medicine.

 

Vaccines

Phase 3 candidates:
 
The European Medicines Agency…

Mentions:
Covid-19, vaccines, drugs, diagnostics, COVAX Facility, Lilly, Regeneron, FDA, EMA, Pfizer, BioNTech, AstraZeneca, Moderna, Fiocruz, Dr. Reddy’s, Finlay Institute, ViroVax, Technovalia, BioNet, PharmaJet, CAMS, Kindred Biosciences, Vaxart, Recipharm, Arcturus, J&J, Janssen, Rentschler Biopharma, HDT Bio, NIAID, Shenzhen Genius Biotech, Gavi, COVAX AMC, WHO, Gilead, BMGF, COVID-19 Therapeutics Accelerator, Fujifilm Diosynth, AbCellera, Junshi, CSL Behring, Emergent BioSolutions, Grifols, Takeda, Vir Biotechnology, ARCA Biopharma, Atea Pharmaceuticals, TLC, Noxopharm, Caladrius Biosciences, Revelation Biosciences, Fosun, Sorrento, ViralClear, BioSig, NIMR, Beckman Coulter, BARDA, Cepheid, Quidel, NIH, RADx, Dascena, Abbott, WTO, USAID, Tufts, NCI, SeroNet, Fred Hutchinson
Read more
Chile challenges Gilead’s hep C patent

STAT reported this week that Chile is the latest country to challenge Gilead’s patents for hepatitis C treatment after the country’s health minister endorsed a resolution to grant compulsory licenses for the company’s blockbuster sofosbuvir drug based on exclusions in the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS).

In September 2017, Malaysia became the first country to grant a compulsory license to manufacture a generic version of…

Mentions:
Gilead, hep C, drugs, TRIPS, WTO
Read more
Subscribe to WTO